BTK and hematologic disorder: Following booster immunization, the low rates of achieving an antibody response were also observed for patients with hematological malignancies who were on Bruton’s tyrosine kinase (BTK) inhibitors (n = 404, ES 45% [95% CI: 25–65%]) (Figure S44), while high rates of immune response were observed with autologous SCT (n = 126, ES 65% [95% CI: 32–93%]) (Figure S45).